Literature DB >> 7826944

Intravenous injection of irradiated Leishmania major into susceptible BALB/c mice: immunization or protective tolerance.

T Aebischer1, L Morris, E Handman.   

Abstract

It is well established that BALB/c mice can be protected from fatal infection with Leishmania major by prophylactic intravenous (i.v.) immunization with irradiated parasites. Protection is critically dependent on the route of injection with i.v. injection being protective and subcutaneous injection not protective. We used this BALB/c-L. major model system to investigate this phenomenon. We analyzed quantitatively the parasite-specific, CD4+ T cell mediated immune responses by limiting dilution. Subcutaneous vaccination resulted in priming of CD4+ precursor T cells, whereas i.v. vaccination was ineffectual. Moreover, i.v. injection prevented the increase in the number of specific precursor cells induced by infection of normal mice during the first weeks post-challenge with virulent parasites. We show here that this was not due to the elimination of the virulent challenge parasites as a result of immunity nor to inefficient antigen presentation of the irradiated organisms after i.v. injection. The data presented here suggest that i.v. injection results in tolerization rather than immunization. Tolerization as a mechanism of host protection is consistent with earlier observations that transient immunosuppression results in cure of L. major infection in BALB/c mice. Transfer of antigen presenting cells (APC) isolated from spleens of mice injected previously with irradiated parasites mimicked to some extent the effect of i.v. immunization with irradiated parasites. The possible involvement of these APC in decreasing the parasite-specific T cell response is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7826944     DOI: 10.1093/intimm/6.10.1535

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  7 in total

1.  Enhancement of experimental cutaneous leishmaniasis by Leishmania molecules is dependent on interleukin-4, serine protease/esterase activity, and parasite and host genetic backgrounds.

Authors:  Virgínia M G Silva; Daniela F Larangeira; Pablo R S Oliveira; Romina B Sampaio; Paula Suzart; Jorge S Nihei; Márcia C A Teixeira; José O Mengel; Washington L C dos-Santos; Lain Pontes-de-Carvalho
Journal:  Infect Immun       Date:  2010-12-20       Impact factor: 3.441

2.  Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.

Authors:  T Aebischer; M Wolfram; S I Patzer; T Ilg; M Wiese; P Overath
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

3.  Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.

Authors:  K J Stacey; J M Blackwell
Journal:  Infect Immun       Date:  1999-08       Impact factor: 3.441

4.  Development of Vaccines against Visceral Leishmaniasis.

Authors:  Krystal J Evans; Lukasz Kedzierski
Journal:  J Trop Med       Date:  2011-09-05

5.  Immunization with L. sigmodontis microfilariae reduces peripheral microfilaraemia after challenge infection by inhibition of filarial embryogenesis.

Authors:  Sebastian Ziewer; Marc P Hübner; Bettina Dubben; Wolfgang H Hoffmann; Odile Bain; Coralie Martin; Achim Hoerauf; Sabine Specht
Journal:  PLoS Negl Trop Dis       Date:  2012-03-06

6.  Leishmania braziliensis and Leishmania amazonensis amastigote extracts differ in their enhancement effect on Leishmania infection when injected intradermally.

Authors:  Cintia F de Araújo; Virgínia M G Silva; Andre Cronemberger-Andrade; Luciana S Aragão-França; Viviane C J Rocha; Priscila S L Santos; Lain Pontes-de-Carvalho
Journal:  BMC Res Notes       Date:  2014-02-01

Review 7.  Cutaneous Manifestations of Human and Murine Leishmaniasis.

Authors:  Breanna M Scorza; Edgar M Carvalho; Mary E Wilson
Journal:  Int J Mol Sci       Date:  2017-06-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.